156 related articles for article (PubMed ID: 33632786)
1. UK paediatric oncology
Proudfoot RH; Phillips B
Arch Dis Child; 2021 Oct; 106(10):994-998. PubMed ID: 33632786
[TBL] [Abstract][Full Text] [Related]
2. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
[TBL] [Abstract][Full Text] [Related]
3. UK survey of Pneumocystis jirovecii pneumonia (PJP) prophylaxis use in paediatric oncology patients.
Proudfoot R; Cox R; Phillips B; Wilne S
Arch Dis Child; 2015 Jan; 100(1):115. PubMed ID: 25324566
[No Abstract] [Full Text] [Related]
4. Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors.
Proudfoot R; Phillips B; Wilne S
J Pediatr Hematol Oncol; 2017 Apr; 39(3):194-202. PubMed ID: 28267082
[TBL] [Abstract][Full Text] [Related]
5. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.
Basiaga ML; Ross ME; Gerber JS; Ogdie A
J Pediatric Infect Dis Soc; 2018 Dec; 7(4):283-289. PubMed ID: 28992298
[TBL] [Abstract][Full Text] [Related]
7. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
Awad M; Sierra CM; Mesghali E; Bahjri K
J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
[TBL] [Abstract][Full Text] [Related]
8. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
Avino LJ; Naylor SM; Roecker AM
Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia.
Nazir HF; Elshinawy M; AlRawas A; Khater D; Zadjaly S; Wali Y
J Pediatr Hematol Oncol; 2017 Apr; 39(3):203-208. PubMed ID: 28234744
[TBL] [Abstract][Full Text] [Related]
10. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Urbancic KF; Pisasale D; Wight J; Trubiano JA
Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
[TBL] [Abstract][Full Text] [Related]
11. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
Geerlinks AV; Campigotto A; Science M; Gupta S
Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature.
Gupta D; Zachariah A; Roppelt H; Patel AM; Gruber BL
J Clin Rheumatol; 2008 Oct; 14(5):267-72. PubMed ID: 18679133
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of effectiveness, hyperkalaemia, and hepatotoxicity of trimethoprim-sulphamethoxazole prophylaxis for Pneumocystis jirovecii pneumonia in paediatric patients: A single-centre retrospective study.
Kato H; Hagihara M; Asai N; Mikamo H; Iwamoto T
Int J Antimicrob Agents; 2024 May; 63(5):107151. PubMed ID: 38508538
[TBL] [Abstract][Full Text] [Related]
14. Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?
Pereda CA; Nishishinya-Aquino MB; Brito-García N; Díaz Del Campo Fontecha P; Rua-Figueroa I
Rheumatol Int; 2021 Aug; 41(8):1419-1427. PubMed ID: 33656582
[TBL] [Abstract][Full Text] [Related]
15. The role of CD4 cell count as discriminatory measure to guide chemoprophylaxis against Pneumocystis jirovecii pneumonia in human immunodeficiency virus-negative immunocompromised patients: A systematic review.
Messiaen PE; Cuyx S; Dejagere T; van der Hilst JC
Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28035717
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis for Pneumocystis jiroveci pneumonia: is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?
Liebling M; Rubio E; Ie S
Expert Rev Respir Med; 2015 Apr; 9(2):171-81. PubMed ID: 25771943
[TBL] [Abstract][Full Text] [Related]
17. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.
Cooley L; Dendle C; Wolf J; Teh BW; Chen SC; Boutlis C; Thursky KA
Intern Med J; 2014 Dec; 44(12b):1350-63. PubMed ID: 25482745
[TBL] [Abstract][Full Text] [Related]
18. Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.
Quinn M; Fannin JT; Sciasci J; Bragg A; Campbell PK; Carias D; Crews KR; Gregornik D; Jeha S; Maron G; Pauley JL; Swanson HD; Wolf J; Greene W
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866879
[No Abstract] [Full Text] [Related]
19. Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.
Lingaratnam SM; Slavin MA; Thursky KA; Teh BW; Haeusler GM; Seymour JF; Rischin D; Worth LJ
Leuk Lymphoma; 2015 Jan; 56(1):157-62. PubMed ID: 24717111
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.
Sierra CM; Daiya KC
Pharmacotherapy; 2022 Nov; 42(11):858-867. PubMed ID: 36222368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
